<--- Back to Details
First PageDocument Content
Toxicology / Toxicity / Animal testing / National Institutes of Health / Donald E. Ingber / Medicine / Science / Scientific method
Date: 2014-04-30 12:51:38
Toxicology
Toxicity
Animal testing
National Institutes of Health
Donald E. Ingber
Medicine
Science
Scientific method

2nd annual meeting agenda

Add to Reading List

Source URL: www.ascctox.org

Download Document from Source Website

File Size: 964,53 KB

Share Document on Facebook

Similar Documents

Glyphosate Research Scoping Background Materials: NTP Technical Report on Toxicity Studies of Glyphosate (CAS NoAdministered in Dosed Feed to F344/N Rats and B6C3F1 Mice, NTP Toxicity Reports Series No. 16,

Glyphosate Research Scoping Background Materials: NTP Technical Report on Toxicity Studies of Glyphosate (CAS NoAdministered in Dosed Feed to F344/N Rats and B6C3F1 Mice, NTP Toxicity Reports Series No. 16,

DocID: 1vr6n - View Document

IN THIS ISSUE Chemical Reaction Reducing the use of animals in toxicity testing Watershed Moment McDonald’s announces plans to

IN THIS ISSUE Chemical Reaction Reducing the use of animals in toxicity testing Watershed Moment McDonald’s announces plans to

DocID: 1vk7D - View Document

Low Toxicity Substances If ingested: What to do: These substances are considered to be of low toxicity when ingested acutely. They may cause oral irritation and mild gastrointestinal upset but other features are unlikely

Low Toxicity Substances If ingested: What to do: These substances are considered to be of low toxicity when ingested acutely. They may cause oral irritation and mild gastrointestinal upset but other features are unlikely

DocID: 1vhFH - View Document

Risk Anulvsis, 5. No. 4, I985  Letter to the Editor Toxicity and Carcinogenic Potency Leslie Bernstein,“) Lois S. Gold,(2) Bruce N. Arnes,(’) Malcolm C. Pike,(3) and David G.

Risk Anulvsis, 5. No. 4, I985 Letter to the Editor Toxicity and Carcinogenic Potency Leslie Bernstein,“) Lois S. Gold,(2) Bruce N. Arnes,(’) Malcolm C. Pike,(3) and David G.

DocID: 1vdoU - View Document

# 3083 AGI-134, a fully synthetic α-Gal-based cancer immunotherapy that shows synergy with anti-PD-1 and favorable pre-clinical pharmacokinetic and toxicity profiles Sascha A. Kristian 1,*,#, Stephen M. Shaw 1,*, Kim Wi

# 3083 AGI-134, a fully synthetic α-Gal-based cancer immunotherapy that shows synergy with anti-PD-1 and favorable pre-clinical pharmacokinetic and toxicity profiles Sascha A. Kristian 1,*,#, Stephen M. Shaw 1,*, Kim Wi

DocID: 1vdls - View Document